Your session is about to expire
← Back to Search
SBRT + Pembrolizumab for Lung Cancer
Study Summary
This trial is studying how well SBRT plus pembrolizumab (MK-3475) works in treating patients with unresected stage I or II non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 27 Patients • NCT01926197Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: SBRT+Pembolizumab
- Group 2: SBRT+Placebo
Frequently Asked Questions
What types of cancer does Stereotactic Body Radiotherapy (SBRT) target most often?
"SBRT is a type of radiotherapy used to target malignant neoplasms. However, it has also been used to treat other conditions such as unresectable melanoma and microsatellite instability high."
Are researchers currently recruiting participants for this trial?
"The study is recruiting patients, as advertised on clinicaltrials.gov. This particular trial was first posted on June 25th, 2019 and has had its information updated as recently as October 12th, 2020."
What are the effects that researchers are hoping to see from this clinical trial?
"The primary outcome of this long-term trial (68 months) will be Event-free Survival (EFS), which will be monitored closely. Additionally, the study will secondary objectives including changes in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Dyspnea (Item 8) Score, Time to Death or Distant Metastases (TTDM), and Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/Quality of"
How many participants are allowed in this clinical trial?
"In order to complete this clinical trial, 530 willing and eligible patients are required. Those that meet the specified inclusion criteria can choose to participate at sites like Sault Area Hospital (Site 0101) in Sault Ste Marie, Ontario and Lankenau Medical Center (Site 3041) in Wynnewood, Pennsylvania."
Has the FDA sanctioned Stereotactic Body Radiotherapy (SBRT) for use?
"There is some evidence from past clinical trials to support the efficacy of SBRT, and it has received multiple rounds of support for its safety, so our team at Power has given it a 3."
Are there any other examples in which Stereotactic Body Radiotherapy (SBRT) has been used?
"SBRT was first trialled a decade ago, at City of Hope. Since then, there have been 18,486 completed studies on the topic. At the moment, there are 999 ongoing studies, with many of them taking place in Sault Ste Marie, Ontario."
Could you inform me as to how many different hospitals are running this experiment?
"Sault Area Hospital (Site 0101), Lankenau Medical Center (Site 3041), Trillium Health Partners - Credit Valley Hospital (Site 0102), and 31 other locations are participating in this trial."
Share this study with friends
Copy Link
Messenger